Patents by Inventor Nicholas Uth

Nicholas Uth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230204421
    Abstract: The monitoring and control of bioprocesses is provided. The present disclosure provides the ability to generate generic calibration models, independent of cell line, using inline Raman probes to monitor changes in glucose, lactate, glutamate, ammonium, viable cell concentration (VCC), total cell concentration (TCC) and product concentration. Calibration models were developed from cell culture using two different CHOK1SV GS-KO™ cell lines producing different monoclonal antibodies (mAbs). Developed predictive models, qualified using an independent CHOK1SV GS-KO™ cell line not used in calibration, measured changes in glucose, lactate, ammonium, VCC, and TCC with minor prediction errors over the course of cell culture with minimal cell line dependence. The development of these generic models allows the application of spectroscopic PAT techniques in a clinical manufacturing environment, where processes are typically run once or twice in GMP manufacturing based on a common platform process.
    Type: Application
    Filed: February 20, 2023
    Publication date: June 29, 2023
    Inventors: Thaddaeus Webster, Brian Hadley, Carrie Mason, Colin Jaques, Seshu Tummala, Ruth Christine Rowland-Jones, Yonatan Levinson, Nicholas Uth, Pankaj Sinha, Eytan Abraham
  • Patent number: 11609120
    Abstract: The monitoring and control of bioprocesses is provided. The present disclosure provides the ability to generate generic calibration models, independent of cell line, using inline Raman probes to monitor changes in glucose, lactate, glutamate, ammonium, viable cell concentration (VCC), total cell concentration (TCC) and product concentration. Calibration models were developed from cell culture using two different CHOK1SV GS-KO™ cell lines producing different monoclonal antibodies (mAbs). Developed predictive models, qualified using an independent CHOK1SV GS-KO™ cell line not used in calibration, measured changes in glucose, lactate, ammonium, VCC, and TCC with minor prediction errors over the course of cell culture with minimal cell line dependence. The development of these generic models allows the application of spectroscopic PAT techniques in a clinical manufacturing environment, where processes are typically run once or twice in GMP manufacturing based on a common platform process.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: March 21, 2023
    Assignee: Lonza Ltd
    Inventors: Thaddaeus Webster, Brian Hadley, Carrie Mason, Colin Jaques, Seshu Tummala, Ruth Christine Rowland-Jones, Yonatan Levinson, Nicholas Uth, Pankaj Sinha, Eytan Abraham
  • Publication number: 20220389363
    Abstract: A filter apparatus is disclosed for withdrawing a fluid medium from a bioreactor during the growth of a cell culture within the bioreactor. Also disclosed is a method for culturing cells in a bioreactor. The filter apparatus includes a hollow tubular member attached to a filter member. The filter member has a pore size and volume capable of withdrawing a fluid medium at a relatively high flow rate from the bioreactor. Without withdrawing biological cells from the bioreactor and without damaging or harming the cells. The filter apparatus of the present disclosure allows for many process improvements.
    Type: Application
    Filed: January 8, 2021
    Publication date: December 8, 2022
    Inventors: Yonatan Levinson, Alex Sargent, Nicholas Uth, Farjad Shafighi
  • Publication number: 20190137338
    Abstract: The monitoring and control of bioprocesses is provided. The present disclosure provides the ability to generate generic calibration models, independent of cell line, using inline Raman probes to monitor changes in glucose, lactate, glutamate, ammonium, viable cell concentration (VCC), total cell concentration (TCC) and product concentration. Calibration models were developed from cell culture using two different CHOK1SV GS-KO™ cell lines producing different monoclonal antibodies (mAbs). Developed predictive models, qualified using an independent CHOK1SV GS-KO™ cell line not used in calibration, measured changes in glucose, lactate, ammonium, VCC, and TCC with minor prediction errors over the course of cell culture with minimal cell line dependence. The development of these generic models allows the application of spectroscopic PAT techniques in a clinical manufacturing environment, where processes are typically run once or twice in GMP manufacturing based on a common platform process.
    Type: Application
    Filed: October 5, 2018
    Publication date: May 9, 2019
    Inventors: Thaddaeus Webster, Brian Hadley, Carrie Mason, Colin Jaques, Seshu Tummala, Ruth Christine Rowland-Jones, Yonatan Levinson, Nicholas Uth, Pankaj Sinha, Eytan Abraham